- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Sofosbuvir ( Sofosbuvir )
Sofosbuvir is a direct-acting antiviral agent that inhibits the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. It is indicated as a component of combination antiviral therapy for the treatment of chronic hepatitis C virus infection in adults and children aged 3 years and older. Sofosbuvir is a nucleotide prodrug that is intracellularly converted to its active triphosphate form, causing chain termination during HCV RNA synthesis. It is active against all major HCV genotypes. Sofosbuvir is never used as monotherapy; it must be combined with other agents such as ribavirin, ledipasvir, velpatasvir, or daclatasvir, depending on the genotype and clinical profile.
Usual adult dose: The recommended dose of sofosbuvir is 400 mg taken orally once daily with or without food. The tablet should be swallowed whole. The specific combination regimen and duration of treatment are determined by HCV genotype, prior treatment history, presence of cirrhosis, and co-infection status. Treatment durations commonly range from 12 to 24 weeks. Sofosbuvir must not be used alone. If a dose is missed and the next dose is not due within 12 hours, the missed dose should be taken as soon as remembered. No dose adjustment is required for mild or moderate renal impairment; in patients with severe renal impairment or end-stage renal disease on hemodialysis, sofosbuvir can be used without dose adjustment, but caution is advised because the major inactive metabolite, GS-331007, accumulates. No dose adjustment is required for mild to moderate hepatic impairment; in decompensated cirrhosis, treatment should be managed by a specialist.
Dosage form: Film-coated tablets: 400 mg (yellow, capsule-shaped, debossed with "SOF" on one side and "400" on the other). Available in bottles of 28 tablets.
Onset of action: Sofosbuvir is rapidly absorbed, with peak plasma concentrations reached approximately 0.5 to 1 hour after oral dosing. Rapid declines in HCV RNA are typically observed within the first weeks of combination therapy. The goal of treatment is sustained virologic response, defined as undetectable HCV RNA 12 weeks after the end of treatment (SVR12), which is considered a virologic cure.
Duration of action: Once-daily dosing maintains therapeutic intracellular concentrations of the active triphosphate. The elimination half-life of the predominant circulating metabolite, GS-331007, is approximately 27 hours, but the pharmacodynamic effect is prolonged. The full treatment course is finite, and SVR12 is assessed after completion.
Alcohol recommendation: Alcohol should be avoided during sofosbuvir therapy. Alcohol may accelerate the progression of underlying liver disease, increase the risk of hepatic decompensation, and impair medication adherence. Patients with chronic hepatitis C should receive counselling on complete alcohol abstinence to optimize treatment outcomes and protect liver function.
Most common side effects: In clinical trials, the most frequently reported adverse effects when sofosbuvir is combined with ribavirin are fatigue, headache, nausea, insomnia, anemia, and pruritus. In interferon-free regimens, the incidence of side effects is generally lower. Anemia is primarily attributable to ribavirin and should be monitored with periodic complete blood counts. Serious bradycardia has been reported when sofosbuvir is co-administered with amiodarone; this combination should be avoided unless no alternative exists, and patients require cardiac monitoring. Sofosbuvir should not be used concurrently with strong P-glycoprotein inducers such as rifampin or St. John's wort, as these may significantly decrease sofosbuvir plasma concentrations and reduce efficacy. Because hepatitis B virus (HBV) reactivation has been reported in HCV/HBV co-infected patients receiving direct-acting antivirals without HBV therapy, all patients should be screened for HBV before starting treatment. Immune reconstitution inflammatory syndrome and hepatic decompensation may occur in patients with advanced cirrhosis. Sofosbuvir is not a cure for all patients and does not prevent transmission of HCV. In Canada, sofosbuvir is available only by prescription and must be prescribed and monitored by a healthcare professional experienced in hepatitis C management.
Would you like to try Sofosbuvir without a prescription?
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
